Arnuity Ellipta Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Arnuity Ellipta Supply Status in 2026

If your patients have been reporting difficulty filling their Arnuity Ellipta prescriptions, you're not alone in hearing these concerns. While Arnuity Ellipta (Fluticasone Furoate inhalation powder) is not currently on the FDA's official drug shortage list, real-world pharmacy availability has been inconsistent for some patients throughout 2025 and into early 2026.

This briefing covers the current supply situation, prescribing implications, cost and access considerations, and practical tools you can use to help your patients maintain uninterrupted asthma control.

Timeline: Key Developments

• August 2014: FDA approves Arnuity Ellipta (100 mcg, 200 mcg) for asthma maintenance in patients aged 12+
• May 2018: FDA approves 50 mcg strength for pediatric patients aged 5-11
• Early 2024: Arnuity Ellipta shortage reported in Canada (resolved)
• July 2025: Prasco Laboratories launches authorized generic (Fluticasone Furoate inhalation powder) in 50 mcg, 100 mcg, and 200 mcg strengths
• March 2026: GSK exclusivity on pediatric labeling data expires; no FDA-listed US shortage

Prescribing Implications

No Formal US Shortage, but Availability Gaps Persist

The absence of an FDA shortage listing doesn't always reflect what patients experience at the pharmacy counter. Several factors are contributing to localized availability issues:

• Brand-to-generic transition: The July 2025 launch of Prasco's authorized generic has created a transitional period where some pharmacies have shifted stocking from brand to generic (or vice versa), resulting in intermittent gaps.
• Formulary shifts: Payers have increasingly moved Arnuity Ellipta to non-preferred or higher-tier positions, requiring prior authorization or step therapy through generic ICS alternatives (typically Budesonide or Fluticasone Propionate). This has reduced overall prescription volume and pharmacy stocking.
• Device-specific manufacturing: The Ellipta dry powder inhaler is a proprietary device, making the supply chain more complex than standard MDI or nebulizer formulations.

Clinical Considerations When Patients Can't Access Arnuity Ellipta

If a patient reports inability to fill their Arnuity Ellipta prescription, consider the following:

1. Authorized generic substitution: The Prasco authorized generic is therapeutically identical (same active ingredient, same device, same strengths). Prescriptions written for Arnuity Ellipta should be substitutable at the pharmacy level, but confirm with the dispensing pharmacy.
2. Therapeutic alternatives: If neither brand nor authorized generic is available, equivalent ICS options include:Budesonide (Pulmicort Flexhaler) — generic available, twice-daily dosing, well-established efficacy
3. Fluticasone Propionate (Flovent Diskus/HFA) — authorized generics available, twice-daily dosing
4. Mometasone Furoate (Asmanex Twisthaler) — once-daily option at certain doses
5. Beclomethasone Dipropionate (Qvar RediHaler) — breath-actuated MDI, twice-daily
6. Dose equivalency: When switching between ICS medications, use established dose equivalency tables. Fluticasone Furoate 100 mcg once daily is generally considered a medium-dose ICS, roughly equivalent to Budesonide 200-400 mcg/day or Fluticasone Propionate 250-500 mcg/day.

Current Availability Picture

Based on pharmacy stocking data and patient reports as of early 2026:

• Large chain pharmacies (CVS, Walgreens, Rite Aid): Variable availability. Some locations carry brand Arnuity Ellipta, some carry the authorized generic, and some carry neither as a regular stock item.
• Independent pharmacies: More flexible ordering capability; often able to source within 1-2 business days through alternative wholesalers.
• Mail-order pharmacies: Generally more reliable inventory for maintenance medications; worth recommending for patients on stable Arnuity Ellipta regimens.
• Authorized generic: Prasco's version is FDA-approved and commercially launched, but pharmacy-level adoption is still ramping up. Not all pharmacies carry it yet.

Cost and Access Considerations

Cost remains a significant barrier for many patients:

• Cash price: $263-$299 per 30-day inhaler (brand)
• With discount coupons: As low as ~$137 (GoodRx)
• GSK For You copay program: Eligible commercially insured patients may pay $0-$10 per fill
• GSK Patient Assistance Foundation: Free medication for qualifying uninsured/underinsured patients (gskpaf.org)
• Insurance coverage: Increasingly subject to prior authorization and step therapy; typical insured copays $25-$75/month

For patients struggling with cost, directing them to savings resources can prevent medication non-adherence. Our guide on saving money on Arnuity Ellipta covers all available options in detail.

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder offers a real-time pharmacy stock-checking tool that your staff or patients can use to locate Arnuity Ellipta availability by zip code. This can be integrated into your discharge workflow to reduce fill failures and callback volume.

Key Resources

• GSK For You: gskforyou.com — copay assistance, free trials
• GSK Patient Assistance Foundation: gskpaf.org — free medication for eligible patients
• FDA Drug Shortage Database: FDA Drug Shortages
• Medfinder Provider Tools: medfinder.com/providers

Looking Ahead

Several developments may affect Arnuity Ellipta availability and prescribing decisions in the coming months:

• Authorized generic adoption: As Prasco's generic gains wider pharmacy distribution, availability and pricing should improve.
• Payer formulary reviews: Upcoming formulary cycles may adjust Arnuity Ellipta's tier placement based on the availability of an authorized generic.
• Pipeline considerations: No new ICS-only inhalers are expected to launch in 2026, but ongoing development of combination ICS/LABA products may shift prescribing patterns for patients needing step-up therapy.

Final Thoughts

While Arnuity Ellipta is not in formal shortage, the real-world availability picture in 2026 is mixed. Proactive communication with patients about pharmacy options, authorized generic substitution, and savings programs can help minimize treatment disruptions.

For additional provider resources, visit Medfinder for Providers or read our companion guide on how to help your patients find Arnuity Ellipta in stock.